- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06517121
tDCS in People With Subthreshold Depression
January 29, 2026 updated by: WONG Man Lok Nichol, Education University of Hong Kong
Personalised Transcranial Direct Current Stimulation to Reduce Daily Loneliness in People With Subthreshold Depression
This study evaluates the effects of multi-session transcranial direct current stimulation on loneliness, mood and depressiveness in people with subthreshold depression.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Depression-prone individuals will be invited and allocated to three groups, either the personalised transcranial direct current stimulation (tDCS) group, the conventional tDCS group, or the sham control group.
After screening and at baseline prior to the tDCS sessions, participants will complete tests and questionnaires on depression symptoms, loneliness and mood.
Eligible participants will also be invited to receive functional magnetic resonance imaging (MRI) in a 3-Tesla MRI scanner.
There will be a maximum of 10 sessions to be completed after the screening and baseline measures.
For both personalised tDCS group and the conventional tDCS group, tDCS with 2 milliampere (mA) intensity will be delivered for 20 minutes in each session.
For sham control group, the protocol will be similar, except that the stimulation only happens in the first 30 seconds in each session.
Especially for participants allocated to the personalised tDCS group, the stimulation site for each individual in this group may vary, depending on their brain activations and connectivity.
The anodal stimulation sites for participants allocated to the conventional tDCS group and the sham control group will be F3 within the left DLPFC.
Immediately after and also 3-months after completing all the tDCS sessions, participants will be invited to complete again tests and questionnaires on depressive symptoms in addition to loneliness and mood.
Eligible participants will also be invited to receive functional MRI scanning in the 3T MRI scanner again.
Participants will also be prompted to self-report daily their loneliness and mood levels throughout the study.
Study Type
Interventional
Enrollment (Estimated)
204
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nichol ML Wong, PhD
- Phone Number: 852-29487431
- Email: nmlwong@eduhk.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- The Education University of Hong Kong
-
Contact:
- Nichol ML Wong, PhD
- Phone Number: 852-29487431
- Email: nmlwong@eduhk.hk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- No histories of learning impairment, major psychiatric disorders including Major Depressive Disorder or neurological disorders
- At least primary school education
- Subthreshold depression
Exclusion Criteria:
- On medication or treatments within 2 weeks prior to the beginning of the study that would affect the individual's brain, cognitive and affective functions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Conventional tDCS group
Participants who are assigned to the Conventional group will receive anodal tDCS over F3.
|
This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time.
Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.
|
|
Sham Comparator: Sham control group
Participants who are assigned to the Conventional group will receive sham tDCS.
The active stimulation will be delivered for the first 30 seconds only.
|
This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time.
Participants assigned to the sham control group will only receive 30 seconds of active stimulation.
|
|
Experimental: Personalised tDCS group
Participants who are assigned to the personalised group will receive anodal tDCS over a individualized stimulation site.
|
This study will deliver tDCS sessions for a maximum of ten sessions in two weeks' time.
Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in self-reported loneliness
Time Frame: From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
Loneliness is assessed based on the University of California, Los Angeles (UCLA) loneliness scale and single item, in which higher scores indicate greater degrees of loneliness.
|
From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in depressive symptoms
Time Frame: From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
Depressive symptoms are assessed based on the Hospital Anxiety and Depression Scale, a 14-item scale assessing severity of depressive and anxiety symptom (score range 0 - 21 for both subscale), with a higher scores indicating higher severity
|
From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
|
Changes in anxiety symptoms
Time Frame: From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
Anxiety symptoms are assessed based on the Hospital Anxiety and Depression Scale, a 14-item scale assessing severity of depressive and anxiety symptom (score range 0 - 21 for both subscale), with a higher scores indicating higher severity
|
From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
|
Changes in self-reported mood
Time Frame: From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
Mood is assessed based on the Chinese Affect Scale, a 20-item 5-point Likert scale where participants rate the degree to which they currently feel the listed affects (scoring for each item: 0 = no at all; 4 = very).
|
From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
|
Changes in brain activation and connectivity
Time Frame: From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
Neural activities and connectivity in Ventral Attention Network, Frontoparietal Network, and Default Mode Network are assessed by functional MRI
|
From baseline to after the last tDCS session; from baseline to 3 months after the last tDCS session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Nichol ML Wong, PhD, Education University of Hong Kong
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 16, 2026
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Study Registration Dates
First Submitted
July 11, 2024
First Submitted That Met QC Criteria
July 22, 2024
First Posted (Actual)
July 24, 2024
Study Record Updates
Last Update Posted (Actual)
February 2, 2026
Last Update Submitted That Met QC Criteria
January 29, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-2024-0048
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subthreshold Depression
-
Fujian Medical UniversityNot yet recruitingSubthreshold DepressionChina
-
University of AlcalaCompletedAnxiety | Depressive Symptoms | Anxiety Symptoms | Subthreshold DepressionSpain
-
Institute of Mental Health, SingaporeNational Medical Research Council (NMRC), SingaporeRecruiting
-
Kibi International UniversityCompletedSubthreshold DepressionJapan
-
Guangdong Provincial Hospital of Traditional Chinese...Unknown
-
Guangzhou Psychiatric HospitalRecruitingTranscranial Direct Current Stimulation | Subthreshold Depression | Young PeopleChina
-
Gunma UniversityCompletedSubthreshold DepressionJapan
-
Kibi International UniversityCompleted
-
King's College LondonBitJamCompletedSubthreshold Depression | Long-term Physical Health ConditionsUnited Kingdom
-
Guangzhou Psychiatric HospitalFifth Affiliated Hospital of Guangzhou Medical UniversityRecruitingDepressive Symptoms | Anxious Symptoms | Subthreshold DepressionChina
Clinical Trials on Personalized Experimental Transcranial Direct Current Stimulation (tDCS)
-
University of PhayaoCompletedIschemic Stroke | Hemorrhagic Stroke | Stroke, CardiovascularThailand
-
The University of Hong KongRecruiting
-
Hebrew SeniorLifeNational Institute on Aging (NIA); Tel Aviv Medical CenterRecruitingMobility Disability | Cognition | Alzheimer Disease and Related DementiasIsrael, United States
-
Charite University, Berlin, GermanyTerminatedNeuralgia | Neuropathic PainGermany
-
Manhattan Psychiatric CenterCompletedSchizophrenia | Auditory HallucinationUnited States
-
D'Or Institute for Research and EducationCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
Oslo University HospitalCompleted
-
NYU Langone HealthNational Institute for Biomedical Imaging and Bioengineering (NIBIB)RecruitingDepressionUnited States
-
The University of Texas at DallasUniversity of Texas Southwestern Medical CenterRecruitingMultiple Sclerosis, Relapsing-RemittingUnited States
-
Charles University, Czech RepublicRecruiting